## 3 Results  
The data analysis revealed a significant association between the presence of oral lichenoid lesions and undergoing pharmacological therapy with statins or satrans (\(\chi^{2}=46.49\); \(p<0.001\)). Specifically, standardized residuals analysis showed that 16.1% of patients on these medications developed the condition compared with only 4.4% of those not taking such drugs (Table 5, Figure 4). This difference between patients taking statins or satrans and those not on these medications was statistically significant. Furthermore, the analysis highlighted a significant association between OLLs and the specific type of medication used (\(\chi^{2}=46.49\); \(p<0.001\)). Based on the results of our study, standardized residual analysis indicated that 16.3% of patients taking statins and 15.9% of those on satrans developed the condition. These percentages are notably higher compared with the 4.4% of cases observed among patients not on similar medications (Table 6, Figure 5). However, the analysis did not show a statistically significant difference in the risk of developing OLLs between patients taking statins and those taking satrans. \begin{table}
\begin{tabular}{c c c c c c} \hline  & \multicolumn{4}{c}{**Drugs, Status or Sartans**} \\ \hline  & & **Frequency** & **Percentage** & **Percentage** & **Cumulative** & **Percentage** \\ \hline  & Other & 87 & 73.7 & 73.7 & 73.7 \\ \cline{2-6} Valid & Statins & 20 & 16.9 & 16.9 & 90.7 \\ \cline{2-6}  & Sartans & 11 & 9.3 & 9.3 & 100.0 \\ \cline{2-6}  & Total & 118 & 100.0 & 100.0 & \\ \hline \end{tabular}
\end{table} 
Table 4: An explanatory table of the cases comparing the total drugs (statins, satrans, or other drugs) taken by patients with a proven diagnosis of lichen planus. \begin{table}
\begin{tabular}{c c c c c c} \hline  & \multicolumn{4}{c}{**OLL**} \\ \hline  & & **Frequency** & **Percentage** & **Percentage** & **Cumulative** & **Percentage** \\ \hline  & No OLL & 2040 & 94.5 & 94.5 & 94.5 \\ \cline{2-6} Valid & OLL & 118 & 5.5 & 5.5 & 100.0 \\ \cline{2-6}  & Total & 2158 & 100.0 & 100.0 & \\ \hline \end{tabular}
\end{table} 
Table 3: A comparison of the total number of people with oral lichenoid lesions (OLLs) or not diagnosed with OLLs. Figure 4: Comparison of the prevalence of oral lichenoid lesions (OLLs) between patients taking statins or sattans (“Drugs”) and those not on these medications (“No drugs”). The percentages indicate the proportion of patients in each category, showing a significantly higher prevalence of OLLs among those on medication (16.1%) compared to those not taking these drugs (4.4%). Figure 5: The proportion of patients who developed oral lichenoid lesions (OLLs) versus those who did not across different drug classes. The blue segments indicate the percentage of patients who developed OLLs, while the red segments show those without OLLs within each drug category. resolved gradually after discontinuation of the drug, reinforcing the role of calcium channel blockers in OLL development [35; 36]. Building on this, a study involving 465 hypertensive patients aged 20-80 years examined the oral conditions associated with antihypertensive therapy. Among the findings, lichenoid drug lesions were identified in 4.5% of patients and were characterized by bilateral, white, linear striations predominantly on the posterior buccal mucosa. These lesions were strongly linked to the use of ACE inhibitors, particularly captopril [32]. In a related study, the correlation between antihypertensive drugs and OLLs was further explored. Among 450 patients undergoing antihypertensive therapy, 3.3% developed OLLs, with lesions primarily affecting the buccal mucosa, labial mucosa, and retromolar regions. Women were disproportionately affected (66.7% vs. 33.3% of men). OLLs typically appear within an average of 3 months after starting antihypertensive therapy and show regression within weeks to months after discontinuing the suspected drug. The most commonly implicated medications included hydrochlorothiazzide, methyldopa, metoprolol, and propranolol.